MX2019010452A - Fabricacion de un producto farmaceutico cristalino. - Google Patents

Fabricacion de un producto farmaceutico cristalino.

Info

Publication number
MX2019010452A
MX2019010452A MX2019010452A MX2019010452A MX2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A
Authority
MX
Mexico
Prior art keywords
manufacture
pharmaceutical product
crystalline pharmaceutical
crystalline
particles
Prior art date
Application number
MX2019010452A
Other languages
English (en)
Inventor
Harteva Merja
Staffans Anna
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61599196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010452(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of MX2019010452A publication Critical patent/MX2019010452A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención actual se refiere a partículas cristalinas de N-((S)-1-(3-(3-cloro-4-cianofenil)-1Hpirazol- 1-il)-propan-2-il)-5-(1-hidroxietil)-1H-pirazol-3-carboxamida (I) que tienen un área de superficie específica (SSA) en el intervalo desde alrededor de 8 hasta alrededor de 16 m2/g, preferiblemente desde alrededor de 10 hasta alrededor de 15 m2/g, y al método para la preparación de tales partículas. El Compuesto (I) es un modulador del receptor de andrógeno (AR) potente que es útil como un medicamento por ejemplo en el tratamiento del cáncer de próstata.
MX2019010452A 2017-03-07 2018-02-27 Fabricacion de un producto farmaceutico cristalino. MX2019010452A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175202 2017-03-07
PCT/FI2018/050143 WO2018162793A1 (en) 2017-03-07 2018-02-27 Manufacture of a crystalline pharmaceutical product

Publications (1)

Publication Number Publication Date
MX2019010452A true MX2019010452A (es) 2019-10-15

Family

ID=61599196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010452A MX2019010452A (es) 2017-03-07 2018-02-27 Fabricacion de un producto farmaceutico cristalino.

Country Status (13)

Country Link
US (1) US11168058B2 (es)
EP (1) EP3592732A1 (es)
JP (1) JP7157071B2 (es)
KR (1) KR20190126111A (es)
CN (1) CN110382467A (es)
AU (1) AU2018229817B2 (es)
BR (1) BR112019018458A2 (es)
CA (1) CA3055019A1 (es)
CL (2) CL2019002540A1 (es)
EA (1) EA201992103A1 (es)
MX (1) MX2019010452A (es)
UA (1) UA126071C2 (es)
WO (1) WO2018162793A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515040A (ja) 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
WO2021001603A1 (en) 2019-07-02 2021-01-07 Orion Corporation Pharmaceutical composition of darolutamide
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
WO2022144926A1 (en) * 2020-12-31 2022-07-07 Msn Laboratories Private Limited, R&D Center Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide
WO2023161458A1 (en) 2022-02-28 2023-08-31 Química Sintética, S.A. Crystalline form of darolutamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304755A1 (en) * 2005-10-27 2009-12-10 Raghu Rami Reddy Kasu Pharmaceutical formulation of losartan
US8883307B2 (en) * 2007-05-28 2014-11-11 Mitsubishi Shoji Foodtech Co., Ltd. Spherical particle of crystalline mannitol
CN102438979A (zh) * 2009-03-12 2012-05-02 麦迪凯姆股份公司 苯甲酰基苯乙酰胺衍生物的新型晶体
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
KR101958177B1 (ko) 2011-04-21 2019-03-15 오리온 코포레이션 안드로겐 수용체 조절성 카복스아미드
KR20140030169A (ko) * 2011-05-04 2014-03-11 머크 샤프 앤드 돔 코포레이션 약물 물질, 제약 조성물 및 그의 제조 방법
EP3250554B1 (en) * 2015-01-30 2022-05-18 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form
SI3495352T1 (sl) 2016-08-26 2021-08-31 Crystal Pharmaceutical (Suzhou) Co., Ltd. Kristalinične oblike antagonista androgenskih receptorjev, postopek njihove priprave in njihova uporaba

Also Published As

Publication number Publication date
AU2018229817A1 (en) 2019-10-24
JP7157071B2 (ja) 2022-10-19
CN110382467A (zh) 2019-10-25
KR20190126111A (ko) 2019-11-08
CL2023002780A1 (es) 2024-01-26
EA201992103A1 (ru) 2020-01-24
JP2020510018A (ja) 2020-04-02
UA126071C2 (uk) 2022-08-10
EP3592732A1 (en) 2020-01-15
AU2018229817B2 (en) 2021-09-30
CA3055019A1 (en) 2018-09-13
WO2018162793A1 (en) 2018-09-13
US20200039940A1 (en) 2020-02-06
US11168058B2 (en) 2021-11-09
BR112019018458A2 (pt) 2020-04-14
CL2019002540A1 (es) 2020-01-31

Similar Documents

Publication Publication Date Title
MX2019010452A (es) Fabricacion de un producto farmaceutico cristalino.
AU2018231032A8 (en) JAK inhibitors containing a 4-membered heterocyclic amide
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
JOP20180025A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019500196A1 (en) Compounds and compositions and uses thereof
MY185488A (en) Process for the preparation of androgen receptor antagonists and intermediates thereof
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
PH12019500198A1 (en) Compounds and compositions and uses thereof
AU2020288559A8 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2019012116A (es) Agentes antifungicos utilizados en combinacion.
ZA202002129B (en) Oral bendamustine formulations
PH12021550258A1 (en) Cdk8/19 inhibitors
PH12020500393A1 (en) Mpges-1 inhibitor for the treatment of osteoarthritis pain
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s